Form 8-K - Current report:
SEC Accession No. 0001193125-21-068571
Filing Date
2021-03-04
Accepted
2021-03-04 08:39:03
Documents
17
Period of Report
2021-03-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d151856d8k.htm   iXBRL 8-K 55369
2 EX-2.1 d151856dex21.htm EX-2.1 424264
3 EX-99.1 d151856dex991.htm EX-99.1 33696
8 GRAPHIC g151856g0304115253275.jpg GRAPHIC 3675
9 GRAPHIC g151856g0304115253490.jpg GRAPHIC 2754
  Complete submission text file 0001193125-21-068571.txt   810342

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA amgn-20210304.xsd EX-101.SCH 3739
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE amgn-20210304_def.xml EX-101.DEF 13561
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE amgn-20210304_lab.xml EX-101.LAB 22599
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amgn-20210304_pre.xml EX-101.PRE 14371
10 EXTRACTED XBRL INSTANCE DOCUMENT d151856d8k_htm.xml XML 6413
Mailing Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Business Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000
AMGEN INC (Filer) CIK: 0000318154 (see all company filings)

EIN.: 953540776 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37702 | Film No.: 21712674
SIC: 2836 Biological Products, (No Diagnostic Substances)